<i><scp>MYD</scp>88</i> wild‐type Waldenstrom Macroglobulinaemia: differential diagnosis, risk of histological transformation, and overall survivalSteven P. Treon, Jorge J. Castillo, Christopher J. Patterson et al.|British Journal of Haematology|2017Cited by 105
BTKCys481Ser drives ibrutinib resistance via ERK1/2 and protects BTKwild-type MYD88-mutated cells by a paracrine mechanismJiaji G. Chen, Guang Yang, Xia Liu et al.|Blood|2018Cited by 84
Ibrutinib discontinuation in Waldenström macroglobulinemia: Etiologies, outcomes, and IgM reboundJoshua Gustine, Jorge J. Castillo, Kirsten Meid et al.|American Journal of Hematology|2017Cited by 73
Prospective Clinical Trial of Ixazomib, Dexamethasone, and Rituximab as Primary Therapy in Waldenström MacroglobulinemiaJorge J. Castillo, Steven P. Treon, Kirsten Meid et al.|Clinical Cancer Research|2018Cited by 68
Ibrutinib withdrawal symptoms in patients with Waldenström macroglobulinemiaJorge J. Castillo, Steven P. Treon, Joshua Gustine et al.|Haematologica|2018Cited by 58